Fundz

CG Oncology Closes $47 Million Series D Financing

PUBLIC · CGONDec 10, 2020

Amount Raised

$47 Million

Round Type

Series D

IrvineBiotechnologyHealth CareTherapeutics

Description

CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing investors ORI Healthcare Fund, Camford Capital and Perseverance Capital Management.

Quick answer

CG Oncology raised $47 Million in a Series D round, dated December 10, 2020. CG Oncology is based in Irvine, California, United States.

How much did CG Oncology raise?
CG Oncology raised $47 Million in a Series D round on December 10, 2020.
What does CG Oncology do?
CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer.
Where is CG Oncology based and how big is it?
CG Oncology is based in Irvine, California, United States. Fundz records about 120 employees.
Who are the decision-makers at CG Oncology?
Fundz holds 3 contacts at CG Oncology, including the President & Chief Operating Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as CG Oncology that raised within 45 days of this round, from Fundz verified event records.

  • Xilio Therapeutics raised $50M on January 21, 2021.
  • Vera Therapeutics, Inc. raised $80M (Series C) on January 19, 2021.
  • SAGE Therapeutics raised $650M on January 15, 2021.
  • NewAmsterdam Pharma raised $196M (Series A) on January 14, 2021.
  • Zevra Therapeutics, Inc. raised $31M on January 13, 2021.
  • Faeth Therapeutics raised $30M (Funding Round) on January 11, 2021.

Who to call at CG Oncology, and when

A new round usually means CG Oncology is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day CG Oncology raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CG Oncology, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CG Oncology. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CG Oncology

Location

Irvine, California, United States

About

CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CG Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsAmbaw B., President & Chief Operating Officer hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for CG Oncology's next move

See what Strategic adds

CG Oncology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.